Ask your AI about this

Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:

Connect your AI · Plans and the 7-day free trial (card required)

Holdings, Q2 2026

Largest first. Common shares only.

Latest 13F holdings
#The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here.Filing
1KMTS
Kestra Medical Technologies, Ltd.
2.73M$69.4M33.6%+1.2%13F ↗
2MLYS
Mineralys Therapeutics, Inc.
1.59M$42.9M20.8%Unchanged13F ↗
3AVLN
Avalyn Pharma Inc.
929,824$30.6M14.8%New13F ↗
4AGMB
AgomAb Therapeutics NV · ADR
1.54M$20.0M9.7%Unchanged13F ↗
5EVMN
Evommune, Inc.
1.39M$18.5M9.0%-26.6%13F ↗
6IVA
Inventiva S.A. · ADR
3.63M$13.7M6.7%+99.8%13F ↗
7ABVX
Abivax SA · ADR
78,125$10.4M5.0%Unchanged13F ↗
8NYXH
Nyxoah SA
522,057$882.3K0.4%Unchanged13F ↗

Changes since Q1 2026

1 new, 2 added to, 1 trimmed, 0 exited, 4 unchanged. By estimated dollars.

New positions (1)

New positions
PositionSharesChangeEst. dollars
AVLN
Avalyn Pharma Inc.
929,824New$30.6M

Added to (2)

Added to
IVA
Inventiva S.A. · ADR
3.63M+99.8%$6.9M
KMTS
Kestra Medical Technologies, Ltd.
2.73M+1.2%$851.9K

Trimmed (1)

Trimmed
PositionSharesChangeEst. dollars
EVMN
Evommune, Inc.
1.39M-26.6%-$6.7M

Exited (0)

None this quarter.

The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.

Compare two quarters

Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.

Reported value by quarter

Value and number of positions at the end of each quarter.

Loading…

Largest positions in earlier quarters

Pick a quarter to see what the fund's biggest positions were then.

Loading…

Ten largest positions

By value, Q2 2026.

$0$20.0M$40.0M$60.0M$80.0MKMTS · Value: $69,417,594KMTSMLYS · Value: $42,949,921MLYSAVLN · Value: $30,609,806AVLNAGMB · Value: $19,972,352AGMBEVMN · Value: $18,499,547EVMNIVA · Value: $13,733,424IVAABVX · Value: $10,410,938ABVXNYXH · Value: $882,276NYXH

Filings

13F filings
Filing
Q2 2026Jul 22, 202613F-HR8$206.5MCurrentSEC ↗
Q1 2026May 11, 202613F-HR7$176.9MCurrentSEC ↗
Q4 2025Feb 17, 202613F-HR5$176.6MCurrentSEC ↗

Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings

Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer